Profile data is unavailable for this security.
About the company
FDC Limited is an India-based company, which is principally engaged in the business of pharmaceuticals. The Company manufactures and distributes its range of generics, formulations, and active pharmaceuticals at its manufacturing plants. It also manufactures oral rehydration salts (ORS) and specialized formulations. It has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. It has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
- Revenue in INR (TTM)20.45bn
- Net income in INR3.14bn
- Incorporated1940
- Employees6.66k
- LocationF D C Ltd142-148, S.V. Road, Jogeshwari (W)MUMBAI 400053IndiaIND
- Phone+91 2 226739100
- Fax+91 2 226300614
- Websitehttps://www.fdcindia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Morepen Laboratories Ltd | 17.45bn | 1.18bn | 47.55bn | 1.62k | 37.55 | -- | 31.77 | 2.73 | 2.31 | 2.31 | 34.26 | -- | -- | -- | -- | 10,749,300.00 | -- | 7.90 | -- | 13.34 | 37.86 | 33.34 | 6.77 | 5.49 | -- | 33.34 | -- | 0.00 | 19.25 | 17.08 | 148.63 | 27.22 | 47.03 | -- |
| Aarti Drugs Ltd | 24.23bn | 1.57bn | 48.29bn | 1.06k | 30.75 | -- | 23.09 | 1.99 | 17.08 | 17.08 | 263.82 | -- | -- | -- | -- | 22,770,740.00 | -- | 9.73 | -- | 15.78 | 34.32 | 22.23 | 6.48 | 8.25 | -- | 7.28 | -- | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Supriya Lifescience Ltd | 5.99bn | 1.35bn | 50.33bn | 448.00 | 37.22 | -- | 33.16 | 8.40 | 16.80 | 16.80 | 74.42 | -- | -- | -- | -- | 13,370,000.00 | -- | 19.08 | -- | 24.04 | 62.75 | 57.12 | 22.58 | 24.71 | -- | 92.47 | -- | 2.88 | 23.74 | 15.47 | 32.56 | 24.75 | 83.79 | -- |
| Aarti Pharmalabs Ltd | 19.50bn | 2.25bn | 59.63bn | 1.63k | 26.47 | -- | 19.78 | 3.06 | 24.86 | 24.86 | 215.17 | -- | -- | -- | -- | 11,983,730.00 | -- | -- | -- | -- | 44.20 | -- | 11.55 | -- | -- | 18.55 | -- | -- | -4.76 | -- | 12.10 | -- | -- | -- |
| Orchid Pharma Ltd | 8.81bn | 1.12bn | 71.16bn | 872.00 | 61.31 | -- | 48.56 | 8.08 | 22.89 | 22.89 | 180.65 | -- | -- | -- | -- | 10,101,540.00 | -- | -0.9734 | -- | -1.40 | 40.67 | 40.74 | 12.78 | -2.40 | -- | 6.08 | -- | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| Sun Pharma Advanced Research Co Ltd | 684.05m | -3.89bn | 71.31bn | 409.00 | -- | -- | -- | 104.25 | -11.97 | -11.97 | 2.11 | -- | -- | -- | -- | 1,672,501.00 | -- | -61.70 | -- | -119.31 | 59.81 | 74.49 | -568.24 | -163.40 | -- | -208.33 | -- | -- | -68.36 | -16.21 | -73.96 | -- | 15.40 | -- |
| Procter & Gamble Health Ltd | 11.51bn | 2.01bn | 85.00bn | 1.41k | 42.31 | 15.79 | 37.22 | 7.38 | 121.01 | 121.01 | 693.20 | 324.24 | 1.21 | 2.71 | 11.45 | -- | 21.21 | -- | 29.28 | -- | 71.29 | -- | 17.46 | -- | 1.90 | 386.94 | 0.0175 | -- | -6.37 | -- | -12.42 | -- | -- | -- |
| Shilpa Medicare Ltd | 11.84bn | 447.57m | 88.20bn | 931.00 | 180.56 | -- | 57.62 | 7.45 | 5.00 | 5.00 | 133.55 | -- | -- | -- | -- | 12,716,850.00 | -- | 2.84 | -- | 3.65 | 65.19 | 60.08 | 3.79 | 7.03 | -- | 1.56 | -- | 10.76 | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Blue Jet Healthcare Ltd | 6.95bn | 1.57bn | 91.16bn | 447.00 | 57.90 | -- | 49.83 | 13.12 | 9.08 | 9.08 | 40.07 | -- | -- | -- | -- | 15,547,110.00 | -- | -- | -- | -- | 55.54 | -- | 22.65 | -- | -- | 124.37 | -- | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| F D C Ltd | 20.45bn | 3.14bn | 94.82bn | 6.66k | 30.31 | -- | 26.67 | 4.64 | 19.21 | 19.21 | 124.56 | -- | -- | -- | -- | 3,070,786.00 | -- | 12.05 | -- | 13.73 | 65.55 | 61.54 | 15.37 | 15.85 | -- | 75.15 | -- | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Strides Pharma Science Ltd | 42.09bn | -475.19m | 125.59bn | 3.07k | -- | -- | 90.91 | 2.98 | -5.44 | 0.4871 | 460.14 | -- | -- | -- | -- | 13,731,270.00 | -- | -1.68 | -- | -2.97 | 60.18 | 51.39 | -1.68 | -3.36 | -- | 1.24 | -- | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Marksans Pharma Ltd | 22.68bn | 3.34bn | 127.44bn | 2.00k | 38.14 | -- | 30.74 | 5.62 | 7.37 | 7.37 | 50.09 | -- | -- | -- | -- | 11,339,960.00 | -- | 14.62 | -- | 18.52 | 53.39 | 50.52 | 14.71 | 14.03 | -- | 32.19 | -- | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Granules India Ltd | 47.01bn | 4.92bn | 132.68bn | 4.12k | 26.98 | -- | 18.87 | 2.82 | 20.29 | 20.29 | 193.87 | -- | -- | -- | -- | 11,403,970.00 | -- | 10.68 | -- | 16.18 | 56.89 | 48.83 | 10.47 | 11.82 | -- | 6.95 | -- | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Akums Drugs and Pharmaceuticals Ltd | -100.00bn | -100.00bn | 133.05bn | 7.39k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.32 | -- | -104.25 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to F D C Ltd's reporting currency: Indian Rupee INR
7.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 10 Sep 2024 | 4.84m | 2.97% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Aug 2024 | 4.30m | 2.64% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 1.07m | 0.66% |
| Tata Asset Management Pvt Ltd.as of 31 Aug 2024 | 471.28k | 0.29% |
| Bandhan Asset Management Co. Ltd.as of 31 Aug 2024 | 462.31k | 0.28% |
| Eastspring Investments (Singapore) Ltd.as of 31 Aug 2023 | 426.14k | 0.26% |
| SSgA Funds Management, Inc.as of 05 Sep 2024 | 335.29k | 0.21% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 282.03k | 0.17% |
| BlackRock Advisors (UK) Ltd.as of 05 Sep 2024 | 151.04k | 0.09% |
| Mellon Investments Corp.as of 05 Sep 2024 | 70.26k | 0.04% |
More ▼
Data from 30 Jun 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
